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MicroRNAs (miRNAs) have recently emerged as key posttranscriptional regulators of gene expression inmul-
ticellular eukaryotes. It is increasingly clear that miRNAs of both viral and cellular origin can positively or neg-
atively influence viral replication. Viral miRNAs can directly alter host physiology, including components of
the immune system, and host miRNAs can directly alter the virus life cycle. Here, we discuss what is known
about how viral and cellular miRNAs influence viral replication and pathogenic potential through their regu-
lation of viral mRNAs or by reshaping cellular gene expression.Introduction
MicroRNAs (miRNAs) are a class of22 nt long noncoding RNAs
transcribed from the genomes of all multicellular organisms and
some viruses (Bartel, 2004; Cullen, 2004). Over 400 different
miRNAs have been identified in humans (Griffiths-Jones et al.,
2006, 2008; Landgraf et al., 2007). miRNA biogenesis begins
with the transcription of a pri-miRNA precursor, typically by RNA
polymerase II (Pol II), containing the mature miRNA sequence
within the stem of an imperfect 80 nt RNA hairpin. The nuclear
RNase III enzyme Drosha, acting in concert with the double-
stranded (ds) RNA-binding protein DGCR8, excises the 60 nt
pre-miRNA hairpin, which is exported to the cytoplasm by Ex-
portin 5. The cytoplasmic RNase III enzyme Dicer then cleaves
the pre-miRNA to give an imperfect, 22 nt long RNA duplex,
featuring 2 nt 30 overhangs on each strand. The miRNA strand,
which generally exhibits weaker 50 base pairing, is preferentially
incorporated into miRNA effector complexes, called RNA-in-
duced silencing complexes (RISCs), consisting minimally of the
miRNA and one of the four Argonaute (Ago) proteins. The unin-
corporated strand, called the passenger or miRNA* strand, is
degraded. If 50 base pairing is similar at both ends of the duplex,
each strand may be incorporated into RISC as a functional
miRNA. The noncanonical generation of pre-miRNAs from short
introns (‘‘mirtrons’’) by splicing and debranching, instead of Dro-
sha-processing, has been described (Berezikov et al., 2007;
Okamura et al., 2007; Ruby et al., 2007). These mirtron-derived
pre-miRNAs are also recognized by Exportin 5 and then pro-
cessed by Dicer.
In animal cells, Ago2-containing RISCs can cleave mRNAs
that are highly complementary to the miRNA. This process is
indistinguishable from RNA interference (RNAi) induced by artifi-
cial small interfering RNAs (siRNAs) (Zeng et al., 2003). However,
miRNA-directed cleavage of mRNAs is rare, and the only exam-
ple of cleavage by a mammalian miRNA thus far is miR-196,
which exhibits a perfect match with its mRNA target (Yekta et al.,
2004). Instead, RISC-bound miRNAs guide the recognition of
partial matches within the 30 untranslated region (30UTR) of target
mRNAs and induce the translational inhibition of these mRNAs,
potentially leading to modest mRNA destabilization. Perfect basepairing of the miRNA ‘‘seed region’’ (nt 2–7 from the miRNA 50
end) to the 30UTR of an mRNA target is often, but not always,
required for miRNA-mediated repression (Lewis et al., 2005). In
many cases, miRNAs and their 30UTR binding sites are evolution-
ary conserved, facilitating the computational identification of
authentic miRNA targets (Rajewsky, 2006). Even though many
miRNAs have been identified and many mRNA targets have
been computationally predicted, the biological significance of
miRNA-mediated regulation is understood in only a few instances.
Nevertheless, specific miRNAs have already been implicated in
diverse biological processes, including development, cellular dif-
ferentiation, proliferation, apoptosis, and oncogenesis (Bushati
and Cohen, 2007). The computational prediction that individual
miRNAs may regulate several hundred genes, and that more
than 30%ofanimal genesmaybe subject to regulation bymiRNAs,
underscores the emerging importance of miRNA-mediated gene
regulation (Krek et al., 2005; Lewis et al., 2005).
miRNAs are attractive candidates as virally encoded regula-
tors of viral and host cell gene expression due to their small
size, their lack of immunogenicity, and their remarkable func-
tional flexibility. It is therefore not surprising that several DNA
viruses have been found to express viral miRNAs. Several sce-
narios for the role of miRNAs in regulating viral replication and
pathogenesis are conceivable. Viral miRNAs may directly regu-
late viral and/or host cell gene expression to benefit the virus
(Figure 1). Viruses may use cellular miRNAs for their replication,
and in some cases the expression of cellular miRNAs may be in-
duced or inhibited to reshape the cellular gene expression envi-
ronment to the benefit of the virus (Figure 2). Finally, the expres-
sion of certain cellular miRNAs may be disadvantageous to the
virus, through their interaction with viral mRNAs or because of
their cellular functions, and may therefore either limit virus repli-
cation or be downregulated by the virus. Regardless of whether
interactions with cellular miRNAs enhance or limit virus replica-
tion, cellular miRNAs may have exerted a significant effect on vi-
ral genome evolution and certainly have the potential to regulate
the tissue tropism of viruses in vivo. This review will discuss
examples of the many roles of miRNAs in interactions between
viruses and their hosts.Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 375
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ReviewFigure 1. Potential Mechanisms of Viral miRNA Function
(A) dsDNA virus-derived miRNAs may target viral transcripts that are transcribed antisense to the miRNA precursor for degradation by RISC (green circle).
(B) Viral miRNAs may inhibit translation of viral transcripts carrying imperfect matches to the miRNA.
(C) Viral miRNAs may engage in novel interactions with host mRNAs (red) or function as orthologs of cellular miRNAs and therefore inhibit the normal mRNA tar-
gets of the orthologous host cell miRNA (purple).Virally Encoded miRNAs
Known viral miRNAs exclusively derive from dsDNA viruses,
mainly of the herpesvirus family, but also from simian polyomavi-
ruses and human adenovirus (Table 1). ThesemiRNAs have been
identified by cDNA cloning of small RNAs from virally infected
cells or based on computational prediction and subsequent val-
idation of their expression.Using analgorithm to identify potential
viral pre-miRNA stem-loop structures, Pfeffer et al. (2005) suc-
cessfully predicted some of the subsequently validated miRNAs
encoded by the virus families listed in Table 1. This report also
predicted pre-miRNA-like hairpin structures in members of the
poxvirus family of dsDNA viruses, but the existence of poxviral
miRNAs has not yet been experimentally validated. Poxviruses
replicate exclusively in the cytoplasm and therefore do not have
ready access to the nuclear stages of the classical miRNA bio-
genesis pathway. It remains possible, however, that poxviruses
have evolved unconventionalmechanismsofmiRNAprocessing.
For other virus families, the probability of encoding miRNAs was
predicted to be low (Pfeffer et al., 2005). Consistent with this hy-
pothesis, miRNA cloning from cells infected with the retroviruses376 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.human immunodeficiency virus type 1 (HIV-1) and human T cell
leukemia virus type 1 (HTLV-1), with the dsDNA virus humanpap-
illomavirus 31 (HPV31), and with two positive-strand RNA
viruses, yellow fever virus (YFV) and hepatitis C virus (HCV), did
not result in the identification of any viral miRNAs (Cai et al.,
2006a; Lin and Cullen, 2007; Pfeffer et al., 2005; Randall et al.,
2007). This is perhaps surprising for HPV, a nuclear dsDNA virus,
but is expected for viruses with RNA genomes, as excision of an
encoded miRNA would result in the degradation of the genomic
RNA. Nevertheless, others have reported the detection of HIV-1
miRNAs (Omoto et al., 2004; Ouellet et al., 2008), and the ques-
tion of whether HIV-1 miRNAs exist remains controversial.
Inspection of Table 1 shows that herpesviruses are currently
unique in expressing multiple viral miRNAs. Herpesviruses are
large (125–240 kb) dsDNA viruses that cause persistent infec-
tions of their host, invariably associated with the establishment
of a reservoir of latently infected cells (Pellett and Roizman,
2007). Viral miRNA expression has been demonstrated for sev-
eral human pathogenic herpesviruses, including Epstein-Barr
virus (EBV), Kaposi’s Sarcoma associated herpesvirus (KSHV),
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ReviewFigure 2. Potential Effect of Cellular
miRNAs on Virus Replication
Cellular miRNAs (purple) may bind viral RNAs and
thereby directly promote viral replication, as in the
case of miR-122, which promotes HCV RNA repli-
cation. Cellular miRNAs may mediate the recogni-
tion of viral mRNAs (red) by RISC (green circle) and
thereby limit virus replication. In this case, viral
mRNAs would likely be under evolutionary pres-
sure to avoid matches to cellular miRNAs abun-
dantly expressed in their physiological host cells.
Finally, cellular miRNAs might indirectly promote
or limit virus replication through regulation of their
endogenous mRNA targets. In this case, viruses
could benefit from reshaping the cellular miRNA
environment.human cytomegalovirus (hCMV), and herpes simplex virus type 1
(HSV-1). Of note, EBV and KSHV are tumorigenic g-herpesvi-
ruses, which establish latency in B lymphocytes and can cause
B cell lymphomas, such as Burkitt’s or Hodgkin’s lymphoma
(by EBV) or primary effusion lymphoma (PEL, can be caused
by KSHV) as well as a range of tumors in other cell types, includ-
ing nasopharyngeal carcinoma (by EBV) and Kaposi’s sarcoma
(by KSHV) (Ganem, 2007; Kieff and Rickinson, 2007). The finding
that cellular miRNAs—so-called oncomirs—can play a role in
cellular transformation raises the possibility that viral miRNAs
could also display oncogenic potential (Gottwein et al., 2007;
He et al., 2005; Skalsky et al., 2007).
Expression of Viral miRNAs
Herpesviral miRNAs derived from noncoding RNAs, from non-
coding regions and open reading frames of protein-coding
mRNAs, as well as from intronic regions, have all been identified.
To date, no viral ‘‘mirtrons’’ have been reported. Like cellular
miRNAs, herpesvirus miRNAs are processed from Pol II tran-
scripts, with the exception of the murine gammaherpesvirus 68
(MHV68) miRNAs, which appear to be derived from RNA poly-
merase III (Pol III) transcripts (Pfeffer et al., 2005). Known adeno-
viral miRNAs derive from the viral VA1 noncoding RNA (Ander-
sson et al., 2005; Aparicio et al., 2006; Sano et al., 2006),
a short Pol III transcript that is expressed at very high levels in in-
fected cells and functions as an inhibitor of cellular protein kinase
R (PKR), an intracellular sensor of dsRNA (Mathews and Shenk,
1991; Thimmappaya et al., 1982). This allows adenovirus to
evade inhibitory cellular responses induced by viral dsRNAs. A
very minor portion of the basal stem of VA1 (<1%) is processed
byDicer into functional RISC-associated small RNAs (Andersson
et al., 2005; Aparicio et al., 2006; Sano et al., 2006). The transfec-
tion of synthetic 20-O-methyl-modified oligonucleotides anti-
sense to these VA1miRNAs resulted in a reduction of adenovirus
titer (Aparicio et al., 2006). However, due to their high affinity for
RNA, these oligonucleotides might also disrupt VA1 folding and
thereby lead to the loss of other functions of VA1, such as inhibi-
tion of PKR. Therefore, further experiments are required to es-
tablish whether VA1-derived RISC-associated small RNAs arean irrelevant byproduct of VA1 overexpression or whether they
indeed function in the adenoviral life cycle.
The expression of the g-herpesvirusmiRNAs identified to date,
with the exception of the rhesus Rhadinovirus (RRV) miRNAs, is
primarily associated with viral latency (Cai et al., 2005, 2006b;
Grundhoff et al., 2006; Landgraf et al., 2007; Pfeffer et al.,
2004, 2005; Samols et al., 2005; Scha¨fer et al., 2007). In contrast,
the hCMV,murine cytomegalovirus (mCMV), andHSV-1miRNAs
identified to date are all expressed during productive virus
replication (Buck et al., 2007; Cui et al., 2006; Do¨lken et al.,
2007; Dunn et al., 2005; Grey et al., 2005). A report suggesting
that the HSV-1 latency associated transcript (LAT), which is the
only HSV-1 transcript expressed during HSV-1 latency, gives
rise to a miRNA (miR-LAT), was subsequently retracted (Gupta
et al., 2006, 2008). Since no LAT-derived proteins have been
found, it remains an attractive hypothesis that one or more LAT
derived miRNAs exist and are important mediators of HSV-1
latency.
In several cases, viral miRNAs are expressed from polycis-
tronic transcripts, thereby ensuring their coregulation. EBV
miRNAs are grouped into two clusters, which are differentially
expressed in different forms of EBV latency (Cai et al., 2006b;
Grundhoff et al., 2006; Pfeffer et al., 2004). The BART miRNA
cluster contains 20 miRNA precursors within the introns of the
BamA rightward transcripts (BARTs). The BHRF1miRNA cluster,
found adjacent to BHRF1 (BamH1 fragment H rightward open
reading frame 1), contains three miRNA precursors (Cai et al.,
2006b; Grundhoff et al., 2006; Pfeffer et al., 2004). Expression
of the full repertoire of EBV latent proteins, consisting of six
EBV nuclear antigens (EBNAs), three membrane proteins (latent
membrane proteins, LMPs), and two small RNAs (EBERs), is
referred to as the latency III program (Kieff and Rickinson,
2007). The latency III expression pattern is observed in
lymphoblastoid cell lines, resulting from the transformation of
primary B cells by EBV in vitro, as well as in B cell lymphomas
arising in immunocompromised individuals in vivo. More re-
stricted, and therefore less immunogenic, patterns of latent
EBV protein expression (latency I and II programs) have been
described in vitro and in vivo (Kieff and Rickinson, 2007). TheCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 377
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Virus Family Subfamily/Genus Name Host
Number of
Validated Pre-miRNAs Names References
Herpesviruses a/Simplexvirus HSV-1 human 1 miR-H1 (Cui et al., 2006)
a/Mardivirus MDV1 chicken 12 miR-M1 to miR-M12 (Burnside et al., 2006;
Yao et al., 2008)
MDV2 chicken 17 miR-M14 to miR-M30 (Yao et al., 2007)
b/Cytomegalovirus hCMV human 11 miR-UL22A, miR-UL36,
miR-UL70, miR-UL112,
miR-UL148D, miR-US4,
miR-US5-1, miR-US5-2,
miR-US25-1, miR-US25-
2, miR-US33
(Dunn et al., 2005; Grey
et al., 2005; Landgraf
et al., 2007; Pfeffer et al.,
2005)
mCMV murine 18 miR-M23-1, miR-M23-2,
miR-M44-1, miR-M55-1,
miR-M87-1, miR-M95-1,
miR-m01-1 , miR-m01-2,
miR-m01-3, miR-m01-4,
miR-m21-1, miR-m22-1,
miR-m59-1, miR-m59-2,
miR-m88-1, miR-m107-1,
miR-m108-1, miR-
m108-2
(Buck et al., 2007; Do¨lken
et al., 2007)
g1/Lymphocryptoviruses EBV human 23 miR-BART1 to miR-
BART20; miR-BHRF1-1
to miR-BHRF1-3
(Cai et al., 2006b;
Grundhoff et al., 2006;
Pfeffer et al., 2004)
rLCV simian 16 miR-rL1-1 to miR-rL1-16 (Cai et al., 2006b)
g2/Rhadinoviruses KSHV human 12 miR-K12-1 to miR-
K12-12
(Cai et al., 2005;
Grundhoff et al., 2006;
Pfeffer et al., 2005;
Samols et al., 2005)
RRV simian 7 miR-rR1-1 to miR-rR1-7 (Scha¨fer et al., 2007)
MHV68 murine 9 miR-M1-1 to miR-M1-9 (Landgraf et al., 2007;
Pfeffer et al., 2005)
Polyomaviruses SV40 simian 1 miR-S1 (Sullivan et al., 2005)
SA12 simian 1 unnamed (Cantalupo et al., 2005)
Adenoviruses hAV human 1 unnamed (Andersson et al., 2005;
Aparicio et al., 2006;
Sano et al., 2006)expression of the BHRF1 miRNA cluster is associated with the
latency III replication program (Cai et al., 2006b; Xing and Kieff,
2007). In contrast, the BART miRNA cluster is expressed at
very low levels in EBV-infected B cells, but expressed at high
levels in EBV-infected epithelial cells undergoing type II latency
(Cai et al., 2006b; Kim do et al., 2007; Lo et al., 2007).
KSHV expresses at least 12 distinct miRNAs during latency
from polycistronic transcripts that also encode the KSHV latent
proteins (Cai and Cullen, 2006). The expression of two KSHV
miRNAs, miR-K12-10 and miR-K12-12, is substantially en-
hanced upon experimental induction of lytic replication by
12-O-tetradecanoyl phorbol-13-acetate (TPA) (Gottwein et al.,
2006; Pfeffer et al., 2005). The biological significance of the
observed TPA responsiveness of KSHV miR-K12-10 and miR-
K12-12, as well as some EBV miRNAs, is unknown.
Unlike the clustered miRNAs seen in KSHV and EBV, the
hCMV andmCMVmiRNAs are scattered throughout the viral ge-
nome and are expressed in lytically infected fibroblasts (Buck378 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.et al., 2007; Do¨lken et al., 2007; Dunn et al., 2005; Grey et al.,
2005; Pfeffer et al., 2005). In most cases, expression of these
miRNAs occurs during the early phase of the viral life cycle, as
indicated by the loss of miRNA expression upon treatment of
cells with cycloheximide, an inhibitor of protein synthesis, which
blocks the production of the immediate early viral proteins re-
quired for early gene expression (Buck et al., 2007; Do¨lken
et al., 2007; Grey et al., 2005). In the case of hCMV and
mCMV, aswell as HSV-1, the examination of viral miRNA expres-
sion during latency is hampered by the lack of appropriate cell
culture systems. Taken together, accumulating evidence sug-
gests that different viral miRNAs may have roles during both viral
latency and productive infection. Herpesviral latency is charac-
terized by highly restricted viral protein expression, thereby re-
ducing the visibility of the virus to the host immune system.
The expression of viral miRNAs during latency may therefore
provide herpesviruses with a nonimmunogenic way to stably
modify their cellular environment. miRNAs expressed exclusively
Cell Host & Microbe
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than those expressed during viral latency. Since miRNAs act at
the mRNA level and do not directly affect the expression of
pre-existing proteins, miRNAs expressed during the relatively
brief productive replication cycle may be more likely to target
viral transcripts, cellular mRNAs for proteins induced by viral
replication, or proteins with a short half-life.
Evolutionary Conservation of Viral miRNAs
The sequences of cellular miRNAs, and of their mRNA target
sites, are frequently highly conserved (Lewis et al., 2005). In
contrast, herpesviral miRNA sequences are generally poorly
conserved (Cai et al., 2005, 2006b; Scha¨fer et al., 2007). How-
ever, in closely related viruses, such as EBV and rhesus lym-
phocryptovirus (rLCV), KSHV and RRV, and Marek’s disease vi-
rus type 1 (MDV-1) and MDV-2, the location of miRNA loci are
conserved (Burnside et al., 2006; Cai et al., 2005, 2006b; Scha¨-
fer et al., 2007; Yao et al., 2007, 2008). rLCV, which diverged
from EBV at least 13 million years ago, encodes miRNAs that
are arranged in a similar fashion and in the same genomic loca-
tion as in EBV (Cai et al., 2006b). Of the 23 validated EBV miR-
NAs and 16 validated rLCV miRNAs, 8 are conserved at the
level of the mature miRNA sequence (Cai et al., 2006b). RRV
represents the closest KSHV relative for which miRNA expres-
sion has been examined so far. While the known RRV miRNAs
are encoded in the same genomic region as in KSHV, they do
not exhibit sequence homology (Scha¨fer et al., 2007). The
chicken a-herpesviruses MDV-1 and MDV-2 diverged at least
26 million years ago (Yao et al., 2007). The miRNAs encoded
by these viruses are clustered in homologous regions of the vi-
ral genomes, which are transcribed during viral latency, but
again are not homologous in sequence (Burnside et al., 2006;
Yao et al., 2007, 2008). In contrast to the clustered miRNAs
seen in g-herpesviruses, the b-herpesviruses hCMV and
mCMV encode miRNAs that are dispersed throughout the virus
genomes, at mostly different locations, and exhibit no evident
sequence homology (Buck et al., 2007; Do¨lken et al., 2007;
Dunn et al., 2005; Grey et al., 2005; Pfeffer et al., 2005). While
several of the hCMV pre-miRNA stem loops and mature miRNA
sequences are predicted to be conserved in chimpanzee CMV,
these miRNAs have not been validated experimentally (Grey
et al., 2005; Pfeffer et al., 2005).
The lack of conservation of viral miRNA sequences does not
necessarily indicate that these miRNAs do not have important
or even, in cases with similar expression patterns, similar func-
tions. Since herpesviruses are highly adapted to their specific
host, there should not be strong evolutionary pressure to tar-
get regions of cellular transcripts that are highly conserved
and any given transcript could conceivably be targeted
through diverse 30UTR sites. In addition, miRNA-mediated re-
pression of cellular genes required for different steps in a single
pathway might have similar biological consequences. Finally,
for viral miRNAs targeting viral transcripts, the miRNA and
the target may have coevolved. Consequently, viral miRNAs
may have very similar functions yet show no sequence identity.
On the other hand, even a single point mutation in the seed
region can lead to a dramatic shift in miRNA function due to
the loss or acquisition of a large number of cellular or viral
mRNA targets. Therefore, it is also possible that viral miRNAfunction exhibits greater evolutionary plasticity than viral pro-
tein function.
Regulation of Viral Gene Expression by Viral miRNAs
Viral miRNAsmay regulate viral transcripts and thereby generate
or fine-tune patterns of viral protein expression (Figures 1A and
1B). Known examples of viral mRNA targets include transcripts
that are transcribed antisense to the viral miRNA precursor
(Barth et al., 2008; Pfeffer et al., 2004; Sullivan et al., 2005). Bind-
ing to the perfectly matched miRNA can therefore target these
transcripts for degradation by Ago2-containing RISC com-
plexes, if they are coexpressed during the virus life cycle. More
recently, other viral transcripts have been shown to be recog-
nized by viral miRNAs through imperfect 30UTR matches (Grey
et al., 2007; Lo et al., 2007; Murphy et al., 2008).
Viral miRNAs Can Induce Degradation
of Viral Transcripts
EBV miR-BART2 was among the first viral miRNAs to be identi-
fied and exhibits perfect complementarity to the 30UTR of the
mRNA for the EBV DNA polymerase BALF5, which is transcribed
antisense to miR-BART2 (Pfeffer et al., 2004). Initial evidence for
cleavage of BALF5 mRNA by miR-BART2 came from the detec-
tion of an unusual BALF5 transcript, the 30 end of which precisely
matched the predicted miR-BART2 cleavage site, upon induc-
tion of productive EBV replication (Furnari et al., 1993). Subse-
quently, BART2-programmed RISC was shown to indeed cleave
BALF5 mRNA (Barth et al., 2008). Since BALF5 is a lytic gene
product, it is unclear whether latently expressed miR-BART2
specifically evolved to target BALF5 and if this interaction is
relevant for the maintenance of EBV latency.
Sullivan et al. (2005) identified one miRNA stem-loop precur-
sor in the genome of the polyoma virus SV40, which gives rise
to two miRNAs (miR-S1-5p and miR-S1-3p) expressed late
during viral infection. Both SV40 derived miRNAs are perfectly
complementary to early mRNAs transcribed antisense to the
pre-miRNA precursor and direct the cleavage of these early tran-
scripts, coding for the large and small T antigens, by RISC
(Figure 1A). SV40 lackingmiRNA expression, due to the selective
disruption of the pre-miRNA structure, expressed higher levels of
early mRNAs and, consequently, higher levels of large and small
T antigen (Sullivan et al., 2005). While the loss of miRNA-medi-
ated downmodulation of T antigen was insignificant for virus rep-
lication, it increased cellular visibility to SV40-specific cytotoxic T
lymphocytes (CTLs), resulting in a higher susceptibility of SV40
miRNA mutant infected cells to CTL killing (Sullivan et al., 2005).
The finding that the polyomavirus simian agent 12 (SA12) ex-
presses a homologous miRNA (Cantalupo et al., 2005), and
that the pre-miRNA hairpin is also conserved in the related BK
virus and JC virus, suggest that polyomavirus miRNAs may pro-
vide a significant advantage to these viruses in vivo (Sullivan
et al., 2005).
In addition to the EBV BALF5 and SV40 T antigen mRNA, sev-
eral other viral transcripts are transcribed antisense to herpesvi-
ral miRNAs and may therefore be regulated similarly (Burnside
et al., 2006; Pfeffer et al., 2005; Yao et al., 2007, 2008). These in-
clude the hCMVUL114 transcript, which is transcribed antisense
to miR-UL112 (Pfeffer et al., 2005). However, coexpression of
UL114 with miR-UL112 may not result in UL114 cleavageCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 379
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evolved to escape regulation by miRNAs with perfect comple-
mentarity, presumably because RNA folding blocks accessibility
to the complementary region. This is consistent with the finding
that target RNA folding is a key determinant of the efficacy of de-
signed siRNAs (Brown et al., 2005). Sequences transcribed anti-
sense to known miRNA stem-loop structures may have an in-
creased propensity to fold into stem-loop structures
themselves. Consequently, possible regulatory relationships be-
tween miRNAs and their antisense mRNA transcripts need to be
individually verified.
Viral miRNAs Can Regulate Viral Transcripts
with Partial Homology
The identification of viral targets of (herpes)viral miRNAs that
are regulated by imperfect matches is more difficult than for
targets with perfectly complementary matches (Figure 1B).
Algorithms used for miRNA target prediction typically detect
conserved matches to the miRNAs (Rajewsky, 2006). Viral
miRNAs are not widely conserved, however, and 30UTR se-
quence conservation between closely related viral species could
be due to other reasons, such as an overlap of transcripts and
regulatory regions. Finally, herpesviral 30UTRs are not well anno-
tated. In the absence of miRNA sequence conservation, the
computational prediction of viral mRNA targets may lead to false
positives due to the fact that the predicted target sites may be
inaccessible.
Grey et al. (2007) computationally predicted target sites for
hCMV miR-UL112 in the 30UTRs of hCMV genes, using an algo-
rithm that calculates the binding energy of miRNAs to candidate
matches. Thirteen candidate target 30UTRs, which were con-
served in chimpanzee CMV, were further screened by 30UTR
luciferase reporter assays. Three of these responded to miR-
UL112, including those from IE72 (IE1) and UL120/121, two
mRNAs encoded within the hCMV major immediate early region
(MIE). The authors went on to demonstrate the specific regula-
tion of an IE72-based reporter, as well as the IE72 protein itself,
by miR-UL112. In contrast, expression of IE86, an immediate
early transactivator expressed from the MIE that lacks a pre-
dicted 30UTR target, was not inhibited. Independently, Murphy
et al. (2008) also computationally predicted IE72 to be a target
for miR-UL112 and validated this interaction using 30UTR indica-
tor assays. Since miR-UL112 is expressed early and accumu-
lates during viral infection (Grey et al., 2005), miR-UL112 may
function to inhibit IE72 expression during the later stage of viral
replication. Murphy et al. (2008) constructed hCMV mutant vi-
ruses in which either miR-UL112 expression was selectively dis-
rupted or which lacked the 7 nt seed match to miR-UL112 in the
30UTR of IE72. Both viruses replicated with wild-type kinetics in
a fibroblast cell line, but exhibited higher levels of IE72 protein
synthesis late during productive infection. While the biological
significance of this finding is currently unclear, the authors
hypothesized that miR-UL112 may promote the transition from
productive replication to latent infection. Interestingly, the
ectopic expression of a synthetic miR-UL112 mimic early during
infection resulted in the reduced expression of a number of
hCMV immediate early proteins, including IE72, but also the non-
targeted IE86 (Grey et al., 2007). This effect was accompanied by
a reduced hCMV genome copy number. miR-UL112 had no ef-380 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.fect onHSV-1 genome copy numbers, thus suggesting no potent
nonspecific effect on general viral replication, e.g., due to induc-
tion of an interferon response. Because this phenotype does not
reflect the pattern of immediate early (IE) gene expression in an
IE72 knockout virus, it is likely that suppression of IE72 expres-
sion bymiR-UL112 is not the sole reason for the observed effect.
Instead, other viral, or possibly cellular, mRNA targets of miR-
UL112 may be important.
Another group recently used computational methods to pre-
dict candidate matches to EBV BART miRNAs in the 30UTR of
EBV latent membrane protein 1 (LMP1) (Lo et al., 2007). LMP1
is expressed during EBV latency and functions as a constitutively
active tumor necrosis factor (TNF) receptor (Kieff and Rickinson,
2007). LMP1 is essential for transformation by EBV in culture and
is believed to contribute to EBV tumorigenesis (Kieff and Rickin-
son, 2007). Of the EBV miRNAs tested, miR-BART-1-5p, miR-
BART-16, and miR-BART-17-5p downmodulated LMP1 protein
expression (Lo et al., 2007). The authors further demonstrated
that altered LMP1 protein levels resulted in the downmodulation
of known LMP1 activities, resulting in an increase in cellular sen-
sitivity to apoptotic stimuli, as well as a decrease in the LMP1-
mediated activation of nuclear factor-kappa B (NF-kB). There-
fore, these miR-BART miRNAs may buffer LMP1 expression
levels, thereby balancing LMP1 growth stimulation and trans-
forming activity with potential toxic effects of the protein. The
significance of this finding in the context of EBV infections
remains unclear.
Regulation of Host Gene Expression by Viral miRNAs
It is possible that some miRNAs have evolved explicitly to regu-
late viral genes and may largely avoid targeting cellular mRNAs.
On the other hand,most viral miRNAswill likely downmodulate at
least some cellular mRNAs and thereby exert physiological ef-
fects (Figure 1C). It is perhaps surprising that so far no viral
miRNA has been found to be perfectly complementary to a cellu-
lar transcript, and to trigger its degradation, since this would pre-
sumably be the most effective way to downregulate a factor that
limits viral replication.
Viral miRNAs are not widely conserved, and, with the notable
exception of viral miRNAs with cellular orthologs (see below),
there is no obvious reason to presume that they target con-
served regions in cellular mRNAs. Because established algo-
rithms for the prediction of targets for cellular miRNAs rely on
conservation of seed matches (Rajewsky, 2006), they may not
be optimal for the prediction of cellular mRNA targets for viral
miRNAs, because they would miss miRNA binding sites that
are not conserved between species. On the other hand, apply-
ing only matching criteria, without considering conservation as
an additional criterion, could result in a large number of false
positive predictions, since many predicted sites might not be
accessible due to mRNA folding. An alternative approach to
mRNA target identification is microarray analysis of cellular
gene expression upon ectopic expression of individual or multi-
ple miRNAs, or after inhibition of miRNA function using anti-
sense reagents, to identify candidate mRNA targets for miRNAs
(Bushati and Cohen, 2007; Krutzfeldt et al., 2005). The main dis-
advantage of this approach is that many authentic targets will
be missed because mRNA levels are not reduced enough for re-
liable detection by microarray analysis. This approach does,
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sequences of miRNA-mediated regulation on cellular gene ex-
pression.
Viral miRNAs Define ‘‘Novel’’ Regulatory Relationships
Samols et al. (2007) performed gene expression profiling of 293
cells stably transfected with a plasmid expressing 10 KSHVmiR-
NAs and found that 65mRNAswere significantly downregulated,
while 8 mRNAs were upregulated. 30UTR analysis showed that
seed matches to the KSHV miRNAs were more common in the
30UTRs of downregulated genes than when 30UTRs were ran-
domly shuffled, suggesting the presence of authentic targets
for viral miRNA regulation. Three of these candidate targets, se-
creted phosphoprotein 1 (osteopontin, SPP1), plasticity related
gene 1 (PRG1) and thrombospondin 1 (THBS1), were further
validated using 30UTR luciferase indicator assays. While the
mRNA for SPP1 was >20-fold downregulated, Samols et al.
did not observe a reduction in the SSP1 protein. THBS1 is an
extracellular matrix glycoprotein with diverse functionsmediated
through manifold interactions with matrix proteins, cytokines,
and cell-associated proteins (Bornstein, 2001). Among other
functions, THBS1 possesses antiangiogenic and antitumori-
genic properties and binds and activates transforming growth
factor b (TGF-b), a multifunctional cytokine (Bornstein, 2001).
The authors observed a >10-fold reduction in THBS1 protein ex-
pression in 293 cells stably expressing the KSHV miRNA cluster
(Samols et al., 2007). Surprisingly, robust derepression of
a THBS1 30UTR luciferase indicator was observed using 20-O-
methyl-RNAs specific for nine out of ten individual miRNAs
encoded in the cluster, which would suggest that each of these
nine KSHV miRNA contributes to full inhibition of THBS1. Based
on the repression of luciferase reporters for TGF-b activity in 293
cells stably expressing the KSHV miRNA cluster, Samols et al.
postulated that reduced levels of THBS1 protein translate into
reduced TGF-b activity. However, the authors did not show
that the reduced TGF-b activity was indeed due to reduced
THBS1 expression. Further studies are therefore needed to
help clarify the role of KSHVmiRNA-mediated THBS1 repression
in physiological target cells for KSHV and the functional
implications of this proposed interaction. Given that Kaposi’s
sarcoma (KS) lesions are characterized by deregulated
angiogenesis (Ganem, 2007), and that KSHV infected PEL cells
are resistant to TGF-b-induced cell-cycle arrest and apoptosis
(Di Bartolo et al., 2008), the repression of THBS1 expression
by KSHV miRNAs may be important for KSHV pathogenesis.
To overcome the current limitations for the computational pre-
diction of cellular mRNA targets for viral miRNAs, Stern-Ginossar
et al. (2007) developed an algorithm that depends on the occur-
rence of multiple binding sites for a single miRNA in cellular
30UTRs and/or stringent matching criteria to identify two cellular
targets for hCMVmiR-UL112. Stern-Ginossar et al. did not report
a comprehensive validation of their algorithm, and it is therefore
hard to estimate the overall performance of their approach. As
discussed above, it seems likely that even stringent matching
criteria would lead to a large number of false positive predictions
if site accessibility is not used as a further criterion. Nevertheless,
this method did identify two interesting cellular targets for miR-
UL112 (Stern-Ginossar et al., 2007). The authors show that
miR-UL112 downregulates major histocompatibility complexclass 1-related chain B (MICB) and, to a lesser extent MICA, ex-
pression. These proteins are stress-induced ligands of the natu-
ral killer (NK) cell activating receptor NKG2D. Ligation of NKG2D
triggers killing of virus-infected cells by NK cells. Consequently,
miR-UL112 specific downregulation of MICB translated into the
reduced susceptibility of virally infected cells to killing by NK
cells (Stern-Ginossar et al., 2007). Of note, several hCMV pro-
teins, including UL16, have previously been implicated in the
escape of hCMV-infected cells from NK cell killing (Wilkinson
et al., 2008), providing an example of functional synergy between
viral proteins and viral miRNAs. MICB is regulated exclusively at
the level of translation, and the interaction with miR-UL112 is
apparently not dependent on an intact seed region (Stern-Ginos-
sar et al., 2007) and would therefore have been missed using mi-
croarray analysis or target prediction algorithms that depend on
seedmatching. AsmiR-UL122 has also been shown to target the
mRNA for the hCMV immediate early protein IE72 (see above)
(Grey et al., 2007; Murphy et al., 2008), hCMV miR-UL112
appears to target both cellular and viral targets at the transla-
tional level.
Viral Orthologs of Cellular miRNAs
Most viral miRNAs do not share seed homology with cellular
miRNAs and therefore likely target novel sites on cellular
mRNAs; i.e., they engage in novel, virus-specific regulatory re-
lationships. However, at least some viral miRNAs seem to have
evolved to hijack existing and, presumably, highly evolved gene
regulatory networks (Figures 1 and 3). It was recently reported
that KSHV miR-K12-11 is an ortholog of cellular miR-155 (Fig-
ure 3). miR-K12-11 and miR-155 are identical along their 50-
terminal 8 nt, i.e., including the entire seed region (Gottwein
et al., 2007; Skalsky et al., 2007). Using microarray analysis
of BJAB cell pools stably expressing levels of miR-K12-11
comparable to those observed in latently KSHV infected PEL
cell lines, miR-K12-11 downregulated genes were specifically
enriched for predicted targets for miR-155 (Gottwein et al.,
2007). A number of microarray-identified candidate target
genes for KSHV miR-K12-11 and a number of previously pre-
dicted targets of miR-155 were similarly regulated by both
miRNAs, as determined by 30UTR luciferase indicator assays,
real time (RT)-PCR, and western blotting. Similar findings
were reported by Skalsky et al. (2007), who showed that the
30UTR of BACH-1, a predicted target of miR-155, responds
equally to both miR-K12-11 and miR-155.
miR-155, the product of theBic gene (Eis et al., 2005), is tran-
siently expressed in macrophages, T and B lymphocytes upon
treatment with inflammatory stimuli, and after T or B cell recep-
tor ligation, and loss of miR-155 expression in knockout mice
revealed defects in adaptive immune responses (Haasch
et al., 2002; O’Connell et al., 2007; Rodriguez et al., 2007;
Thai et al., 2007). Importantly, constitutive expression of miR-
155 in B cells is associated with the development of B cell lym-
phomas in humans, mice, and chickens, leading to the classi-
fication of miR-155 as an oncomir. Bic was first identified as
a gene that is commonly activated by proviral insertion in avian
leukosis virus (ALV) induced B cell lymphomas in chicken (Tam
et al., 1997). Transgenic expression of miR-155 in the B cell
compartment in mice results in the development of B cell lym-
phomas, and miR-155 expression is elevated in several typesCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 381
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well as in other cancers (Costinean et al., 2006; van den Berg
et al., 2003). While the mechanism by which the constitutive ex-
pression of miR-155 in B cells causes tumorigenesis is not un-
derstood, the finding that KSHV miR-K12-11 is an ortholog of
miR-155 raises the possibility that miR-K12-11 may contribute
to the development of KSHV-associated lymphomas. Interest-
ingly, the oncogenic a-herpesvirus MDV-1 encodes a miRNA,
miR-M4, that also shares the same 50-terminal 8 nt, suggesting
that this viral miRNA may also function as an ortholog of miR-
155 in infected chickens (Figure 3). Remarkably, MDV-2, which
lacks a miR-155 ortholog, is not oncogenic in chickens (Schat
and Calnek, 1978). While MDV-1 also encodes other proteins,
such as the meq oncogene, that are not present in MDV-2, it
is tempting to speculate that MDV-1 miR-M4 may contribute
to tumorigenesis in this system. Validated targets for miR-155
include proteins with known roles in B cell function, such as
PU.1, but also a protein with known proapoptotic functions, tu-
mor protein p53 inducible nuclear protein 1 (TP53INP1), which
has been suggested to contribute to the development of miR-
155-expressing pancreatic tumors (Gironella et al., 2007; Vig-
orito et al., 2007). It is interesting that both KSHV miR-K12-11
and MDV-1 miR-M4 only share the first 8 nt with cellular miR-
155. Therefore, it remains possible that functional differences
between these miRNAs exist.
A subset of other viral miRNAs also share sequence homol-
ogy with cellular miRNAs. MHV68 miR-M1-4 shares the 50-ter-
minal 9 nts with murine miR-151, a miRNA of unknown func-
tion (Figure 3). Other seed homologies are more limited, and
extend only over nts 2–7, corresponding to the minimal miRNA
seed region. However, since 6 nt seed base pairing can be
sufficient for the regulation of some targets, these miRNAs
may also share targets with their cellular counterparts. The
most interesting of these miRNAs are EBV miR-BART5, rLCV
miR-rL1-8, and MHV68 miR-M1-7-5p, all of which share perfect
seed homology with cellular miR-18a and miR-18b, encoded
in the miR-17-92 cluster, which also has oncomir function
(Figure 3) (He et al., 2005). Since the seed homology is more
limited, and does not extend to nt 8 of the miRNAs, targets
that depend on base pairing to nt 8 of the miRNA may not
Figure 3. Viral miRNAs with Cellular Orthologs
Seed alignments of viral miRNAs with their known or candidate cellular
orthologs (homologous bases are in red) are shown. KSHV miR-K12-11
functions as an ortholog of cellular miR-155 (Gottwein et al., 2007; Skalsky
et al., 2007). Other potential orthologs of viral miRNAs referred to in the
text are listed. Nucleotides that distinguish hsa-miR-18a from hsa-miR-
18b (not shown) and mmu-miR-18a from mmu-miR-18b (not shown) are
in black and bold. miRNAs are designated as in miRBase (http://
microrna.sanger.ac.uk). Abbreviations: hsa, Homo sapiens (human);
gga, gallus gallus (chicken); mmu, Mus musculus (mouse); mghv, murine
gammaherpesvirus 68 (MHV68).
be shared between these miRNAs. In conclusion, it has
been shown that KSHV miR-K12-11 is an ortholog of cellu-
lar miR-155, and in other cases, similar relationships to
cellular miRNAs are suggested by seed identity to cellular
miRNAs. In these cases, known functions of the suspected
cellular orthologs and computationally predicted targets
of these miRNAs may provide a useful starting point for func-
tional analysis.
Impact of Host miRNAs on Virus Replication
and Pathogenesis
Given the scope of miRNA-mediated gene regulation in the
mammalian system, it is expected that cellular miRNAs also di-
rectly or indirectly affect virus replication and pathogenesis (Fig-
ure 2). Viral genomic RNAs or mRNAs could have evolved to di-
rectly interact with host miRNAs to facilitate certain steps of their
life cycle. In other cases, such interactions would be inhibitory
and viral mRNAs may be under selective pressure to avoid bind-
ing to abundant cellular miRNAs. Finally, the cellular miRNA
composition in infected cells is likely to indirectly affect viruses,
because many pathways that promote or limit viral replication
or the survival of infected cells are likely to be regulated by cel-
lular miRNAs (Figure 2). In either case, viruses may therefore
gain an advantage by reshaping the cellular miRNA composition.
Several recent reports hint at the scope of viral interactions with
host miRNAs and are discussed below.
Viruses May Exploit Direct Interactions
with Host miRNAs
Astrikingexample of a cellularmiRNA required for virus replication
ismiR-122,which facilitates the replicationof thepathogenic, pos-
itive-strand RNA virus HCV (Jopling et al., 2005; Randall et al.,
2007). In mammals, miR-122 expression is confined to the liver,
where it is the most abundant miRNA and may help maintain liver
tissue identity (Esau et al., 2006; Krutzfeldt et al., 2005). miR-122
regulates fatty acid and cholesterol biosynthesis, pathways cen-
tral to liver function and theHCV life cycle (Esau et al., 2006; Krutz-
feldt et al., 2005). Jopling et al. (2005) reported that inhibition of
miR-122 function reducedHCV genotype 1 RNA replication, with-
out notable effects on HCV protein translation or RNA stability.
This dependence on miR-122 function required binding to a site
in the 50UTR of the HCV genomic RNA. The importance of miR-
122 for the complete HCV life cycle was subsequently also con-
firmed in an HCV genotype 2 cell-culture system (Randall et al.,
2007). Furthermore, conservation of the miR-122 binding site in
all six HCV genotypes, which otherwise differ by 30% at the382 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.
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is relevant in vivo (Jopling et al., 2005). Finally, the liver-specific ex-
pression of miR-122 may contribute to the tissue tropism of HCV.
The mechanism for this unusual function of miR-122 in HCV
replication is still unknown. A simple explanation would be an
indirect enhancement of HCV replication caused by the seques-
tration of miR-122 away from its endogenous target mRNAs.
However, while the effect of HCV replication on the regulation
of endogenous miR-122 targets has not been evaluated to
date, the role of miR-122 in HCV RNA replication is likely direct.
While an miR-122 binding-deficient, mutant HCV replicon ex-
hibited reduced RNA replication, this mutant could be rescued
by expression of a miR-122 variant bearing compensatory
base changes (Jopling et al., 2005). More likely scenarios for
miR-122 function in HCV replication therefore include a direct
role of miR-122, or miR-122-associated proteins, in the localiza-
tion and/or replication of HCV genomic RNA. Interestingly, the in-
dividual knockdown of Drosha, DGCR8, Dicer, and of the four
Ago proteins was reported to result in reduced HCV replication
(Randall et al., 2007). However, this finding has not been linked
so far to the requirement for miR-122 function in HCV replication,
and further experiments are needed to delineate any general role
of the miRNA pathway in HCV replication. It will also be interest-
ing to see if other RNA viruses, especially flaviviruses, engage in
similar interactions with host miRNAs.
In a recent report, Huang et al. (2007) proposed that HIV-1
exploits miRNA-mediated regulation to maintain HIV-1 latency
in resting CD4+ T lymphocytes. In acquired immunodeficiency
syndrome (AIDS) patients, a small number of HIV-1-infected ac-
tivated CD4+ lymphocytes return to a quiescent state to become
CD4+ memory T cells. This process is associated with the tran-
scriptional silencing of the integrated HIV-1 genome, due to the
limited activity in these cells of factors required for HIV-1 tran-
scription (Lassen et al., 2004). These authors propose that the
few HIV-1 transcripts produced in these cells are subject to si-
lencing by several cellular miRNAs, specifically miR-150, miR-
28, miR-125b, miR-223, and miR-382, which are overexpressed
in resting CD4+ T lymphocytes compared to their activated
counterparts (Huang et al., 2007). The presence of matches to
these miRNAs in the shared 30 portion of HIV-1 transcripts
conferred miRNA-mediated regulation to luciferase reporters
carrying HIV-1 genome fragments. The inhibition of all of these
miRNAs, using a combination of 20-O-methyl-oligonucleotides,
resulted in increased HIV-1 protein expression and virus produc-
tion from resting CD4+ T cells transfected with infectious HIV-1
clones or from patient-derived resting CD4+ T cells. Since a mu-
tational analysis of the putative miRNA binding sites has not
been reported, it remains possible that the observed effects
are indirect and that these miRNAs regulate CD4+ T cells prop-
erties required for HIV-1 latency. While HIV-1 latency in resting
CD4+ T cells is amajor obstacle to curing HIV-1 by available anti-
retroviral drugs, which invariably target replicating virus, there is
currently no evidence that HIV-1 is under evolutionary pressure
to establish ormaintain a latent reservoir, and therefore the phys-
iological relevance of the proposed interactions is not yet clear.
Antiviral miRNAs?
Another possible scenario is that cellular miRNAs interact with
viral genomic RNAs or mRNAs and thereby inhibit virus replica-tion. Several viruses, including retroviruses, are accessible to in-
hibition by experimentally introduced siRNAs, making it likely
that they are also accessible to inhibition by miRNA-pro-
grammed RISC (Gitlin and Andino, 2003). Viruses may be under
selective pressure to avoid functional binding sites for miRNAs,
which are abundantly expressed in their normal target cells,
and viral genomes are likely optimized for replication in that en-
vironment. This hypothesis suggests that the fortuitous repres-
sion of viral mRNAs by cellular miRNAs present in nontarget tis-
sues could pose a significant hurdle to successful infection and
thereby might serve as a key determinant of viral tissue tropism.
This hypothesis is supported by the finding that engineered
miRNA target sites can regulate the tissue tropism of lentiviral
vectors in vivo (Brown et al., 2006). Similarly, the introduction
of miRNA target sites for two muscle-specific miRNAs into the
genome of the oncolytic picornavirus Coxsackievirus A21
(CVA21) effectively abolished CVA21 replication in murine mus-
cle cells and, consequently, CVA21-induced myositis. In con-
trast, the oncolytic properties of CVA21 in tumor cells lacking
these muscle-specific miRNAs were fully preserved (E. J. Kelly
and S. J. Russell, personal communication).
Several recent reports suggest that replication of wild-type vi-
ruses can also be inhibited by endogenous cellular miRNAs, rais-
ing the question of whether specific cellular miRNAs may have
specifically evolved to limit virus replication. Lecellier et al.
showed that endogenous cellular miR-32, expressed in HeLa
and BHK21 cells, can limit the replication of the retrovirus pri-
mate foamy virus (PFV) in cell culture through an interaction
with a poorly conserved region in the 30 portion of the PFV ge-
nome (Lecellier et al., 2005). It is currently unclear if such an in-
teraction would occur in the natural context and thereby limit
PFV replication. Similarly, Otsuka et al. observed that Dicer
knockout mice are hypersensitive to infection by vesicular sto-
matitis virus (VSV), a negative-strand RNA virus (Otsuka et al.,
2007). This effect was at least partially due to the loss of miR-
24 and miR-93 expression in these mice. Both miRNAs were
shown to downregulate viral mRNAs and mutant VSV, in which
miR-24 and miR-93 binding was abolished, replicated with
higher efficiency in wild-type, but not Dicer knockout, mice.
While this result demonstrates that VSV could be targeted by
miRNAs, there is currently no evidence that these cellular
miRNAs restrict VSV replication in its natural hosts. Finally,
Pedersen et al. (2007) demonstrated that interferon treatment
of hepatocytes causes the upregulation of several cellular
miRNAs, including miR-1, miR-30, miR-128, miR-196, miR-296,
miR-351, miR-431, and miR-448, some of which have seed
matches in the HCV genome. In the case of miR-196 and miR-1,
the kinetics of miRNA expression were analyzed and showed
a transient upregulation of these miRNAs by 3- and 10-fold, re-
spectively, in interferon-b-treated cells compared to untreated
cells. miRNA levels returned to the uninduced status within 24 hr
after interferon treatment. The transfection of HCV replicon-con-
taining hepatocytes with synthetic miRNA mimics for miR-196,
miR-296, miR-351, miR-431, and miR-448 resulted in a 2- to 5-
fold reduction in HCV RNA accumulation. At least in the case of
miR-196andmiR-448, theantiviral effectof the transfectedmiRNA
mimics was correlated with the presence of matches to these
miRNAs in the viral genome. The levels and expression kinetics
of transfected miRNA mimics are likely to be different from theCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 383
Cell Host & Microbe
Reviewtransient expression of the endogenous miRNAs after interferon
induction, and therefore it is currently unclear if this inhibitory
effect would also exist with endogenously expressed miRNAs.
The treatment of HCV replicon-containing hepatocytes with inter-
feron reduces HCV RNA content by about 10-fold, whereas HCV
RNA levels in interferon-treated cells were only marginally in-
creased when these miRNAs were inhibited, suggesting that if
these miRNAs indeed limit HCV replication, they must act in con-
cert with other antiviral mechanisms (Pedersen et al., 2007). Inter-
estingly, miR-122was downregulated by the treatment of hepato-
cytes with interferon. However, rescued miR-122 expression
alone was also not able to rescue HCV replication in interferon-
treated cells (Pedersen et al., 2007). Therefore, the relevance of
the interferon induction or repression of cellular miRNAs to HCV
replication remains unclear. The fact thatmany of the binding sites
for the interferon-inducedmiRNAs are not broadly conserved be-
tween HCV genotypes also suggests that interferons limit HCV
replication primarily through miRNA-independent mechanisms.
It is possible that reported interactions between viruses and
cellular miRNA that result in restriction of viral replication may
have resulted from fortuitous binding in settings that are irrelevant
to the normal cellular targets of the virus in vivo, or that the re-
ported interactions are not likely to be limiting to viral replication.
This hypothesis is underscored by the fact that most of the mi-
RNAs that were reported to have antiviral functions are con-
served in a rangeof organisms that is far broader than the species
tropism of the inhibited viruses, suggesting that host cell miRNA
sequence conservation is due to unrelated selection pressures.
Moreover, viruses should also be able to easily escape such in-
hibitory interactions by mutation and, indeed, rapid viral escape
from experimentally introduced siRNAs has been reported for
a range of viruses (Westerhout et al., 2005). These considerations
suggest that future claims for inhibition of viral replication by en-
dogenous cellular miRNAs will need to carefully address the
physiological relevance of the proposed inhibitory interactions.
Indirect Effects of Host miRNAs
In addition to direct roles of cellular miRNAs in modulating vi-
rus replication, the expression pattern of cellular miRNAs may
also indirectly promote or limit virus replication and/or patho-
genicity by repressing cellular factors that influence these pro-
cesses. It is likely that viruses have evolved ways to selectively
upregulate supportive miRNAs or to downregulate limiting
miRNAs, and thereby optimize the cellular environment for their
replication.
Triboulet et al. (2007) reported that HIV-1 replication in T lym-
phocytes is enhanced in the context of reducedDicer andDrosha
expression, suggesting that cellular miRNAs may limit HIV-1
replication. They further showed that miRNA expression from
the cellular miR-17-92 cluster, comprising miR-17-5p, miR-18,
miR-19a, miR-20a, miR-19b-1, and miR-92-1, is downregulated
in HIV-1-infected T lymphocytes by an unknownmechanism. Ec-
topic expression and/or inhibition of endogenous miRNAs sug-
gested that miR-17-5p andmiR-20a limit HIV-1 replication by re-
ducingPCAFexpression. PCAF, a histone acetyl transferase, has
been proposed to promote HIV-1 transcriptional elongation
(Kiernan et al., 1999). Enhanced PCAF expression does not fully
account for the phenotype induced by Dicer or Drosha knock-
down, however, since the knockdown of Dicer or Drosha, in the384 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.context of a PCAF knockdown, still increased reported gene
expression from an HIV-1 based indicator plasmid (Triboulet
et al., 2007).
While viruses may have evolved to downregulate the expres-
sion of certain cellular miRNAs, they may also upregulate cellular
miRNAs that benefit the virus. Several miRNAs have been re-
ported to be upregulated by HIV-1 infection, with unknown con-
sequences (Triboulet et al., 2007; Yeung et al., 2005). Similarly,
EBV infection results in the upregulation of several cellular miR-
NAs, including miR-146 and miR-155, possibly due to B cell ac-
tivation by EBV (Cameron et al., 2008; Jiang et al., 2006; Yin
et al., 2008). This hypothesis is supported by the finding that
miR-146 induction is a consequence of the activation of NF-kB
by the EBV LMP1 protein (Cameron et al., 2008). The signifi-
cance of the upregulation of these miRNAs for EBV latency,
and their possible role in the induction of EBV-associated tu-
mors, is currently unclear. Interestingly, the tumorigenic herpes-
viruses KSHV, and possibly MDV-1, encode viral orthologs of
miR-155 (Burnside et al., 2006; Gottwein et al., 2007; Skalsky
et al., 2007; Yao et al., 2008). The benefit of miR-155 expression
to these viruses remains to be elucidated, but the expression of
miR-155, or its functional orthologs, may contribute to viral on-
cogenesis in all three systems, with KSHV and MDV-1 encoding
a viral miR-155 ortholog while EBV instead induces expression of
endogenous miR-155.
Conclusions
Viral miRNAs were discovered only recently, and functional rela-
tionships between viruses and viral or cellular miRNAs are only
now beginning to be elucidated. Recent reports suggest that at
least some viral miRNAs evolved to regulate viral gene expres-
sion. Other viral miRNAs affect cellular gene expression by en-
gaging in novel regulatory relationships or by mimicking cellular
miRNAs and thereby utilizing predefined cellular regulatory net-
works. Conversely, cellular miRNAs can alter the viral life cycle,
strikingly exemplified by the fact that host miR-122 facilitates
HCV replication.
Some functions of cellular or viral miRNAs in infected cells will
undoubtedly turn out to be important for virus replication in vivo
and may therefore become targets for therapeutic intervention.
On the other hand, the emerging interface between viruses and
miRNAs may uncover novel pathways that promote or limit virus
replication, and this knowledge could also help to guide drug
design. Antisense inhibitors of miRNA function, which are bio-
available in vivo, such as antagomirs, could represent a good
starting point for the development of miRNA inhibitory drugs
(Gottwein et al., 2007; Krutzfeldt et al., 2005). Antisense inhibi-
tors targeting cellular miRNAs would be predicted to have side
effects, depending on the function of the inhibited miRNA, since
these inhibitors would also disrupt the cellular functions of these
miRNAs. An alternative strategy could be to disrupt the interac-
tion of cellular or viral miRNAswith only one or few of their cellular
or viral target sequences. As for other antiviral drugs, there is
a chance of the virus becoming resistant, e.g., by mutation of
the viral miRNAs or viral binding sites for cellular miRNAs. This
is a particular concern for viruses with high mutation rates,
such as HIV-1 or HCV. In this case, miRNA-based therapeutics,
like other antiviral drugs, would likely be most effective when
used in combination.
Cell Host & Microbe
ReviewMicroRNAs represent a class of molecule produced by both
viruses and their hosts that can benefit either the virus or the
host, depending on the particular interaction. Such interactions
are likely to play key roles in viral pathogenesis, determining
the degree to which hosts restrict viral infections and beingmod-
ified over evolutionary time as the genomes of both host and
pathogen evolve.
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